[Research Progress on the Application Strategies of Plerixafor in the Peripheral Blood Stem Cell Mobilization for Autologous Transplantation--Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 32(1): 322-326, 2024 Feb.
Article
in Zh
| MEDLINE
| ID: mdl-38387943
ABSTRACT
Plerixafor, an analog of C-X-C motif chemokine receptor 4 (CXCR4), which allows the release of stem cells from the bone marrow into peripheral blood (PB) by disrupting the interaction of CXCR4 with stromal cell-derived factor-1 (SDF-1), is effective in mobilization for peripheral blood stem cells (PBSC). Due to its market approval has not been long and its high price in China, the clinical application of plerixafor is still very limited. The clinicians are actively seeking the optimal use of plerixafor to improve the success rate of PBSC collection and reduce the cost. This article reviews the latest research progress related to plerixafor application, in order to summarize the optimal use of plerixafor in autologous hematopoietic stem cell transplantation (auto-HSCT).
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Peripheral Blood Stem Cells
/
Cyclams
/
Heterocyclic Compounds
Limits:
Humans
Language:
Zh
Year:
2024
Type:
Article